Drillon A, et al. Registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancer. Abstract PL02.08. WCLC 2019, 7-10 september, Barcelona, Spanje.
COVID-19-mortaliteit bij kankerpatiënten - impact van behandeling
aug 2020 | Immuuntherapie